
    
      This is a phase II, multi-center, open label, single arm, interventional study. Patients with
      HER2-positive metastatic gastric or gastro-esophageal junction adenocarcinoma who have not
      received prior treatment for metastatic disease will be treated with trastuzumab(8 mg/kg
      loading dose followed by 6 mg/kg every 3 weeks ),Capecitabine(2000mg/m2d, d1-14,every 3
      weeks) and Docetaxel (60mg/m2 every 3 weeks for 6 cycles).All patients will continue to
      receive trastuzumab and Capecitabine until either disease progression, occurrence of
      unacceptable toxicity or withdrawal from the study for another reason.Primary endpoints is
      PFS and secondary endpoints are ORR, OS and Safety.Recruitment period:24 months;PFS follow-up
      period: 80% PFS events;OS follow-up period: 18 months or 80% OS events, whichever occurs
      first.
    
  